Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast

Immunology Letters

Volumn 102, Issue 2, 2006, Pages 229-236

  Leong, Pooi Pooi ^a   Mohammad, Rohaizak ^b   Ibrahim, Naqiyah ^b   Ithnin, Hairuszah ^a   Abdullah, Maha ^a   Davis, William C ^c   Seow, Heng Fong ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Effector; Four colour analysis; Regulatory; Tumour infiltrating lymphocytes

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; INFANT; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ADULT; ANTIGENS, CD28; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CD4-CD8 RATIO; ESTROGEN RECEPTOR ALPHA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 30144436959     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2005.09.006     Document Type: Article

References (41)

1. A. Ghafoor, A. Jemal, E. Ward, V. Cokkinides, R. Smith, and M. Thun Trends in breast cancer by race and ethnicity CA Cancer J Clin 53 2003 342 355
2. Felay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press.
3. R. Bassler, A.M. Dittmann, and M. Dittrich Mononuclear stromal reactions in mammary carcinoma, with special reference to medullary carcinomas with a lymphoid infiltrate. Analysis of 108 cases. Virch Arch A: Pathol Anat Histol 393 1981 75 91
4. H.M. Ogmundsdottir, I. Petursdottir, and I. Gudmundsdottir Interactions between the immune system and breast cancer Acta Oncol 34 1995 647 650
5. G.E. Peoples, S. Blotnick, K. Takahashi, M.R. Freeman, M. Klagsbrun, and T.J. Eberlein T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role Proc Natl Acad Sci USA 92 1995 6547 6551
6. S. Marsigliante, L. Biscozzo, A. Marra, G. Nicolardi, G. Leo, and G.B. Lobreglio Computerized counting of tumor infiltrating lymphocytes in 90 breast cancer specimens Cancer Lett 139 1999 33 41
7. C.N. Baxevanis, G.V. Dedoussis, N.G. Papadopoulos, I. Missitzis, G.P. Stathopoulos, and M. Papamichail Tumor specific cytolysis by tumour infiltrating lymphocytes in breast cancer Cancer 74 1994 1275 1282
8. S.N. Georgiannos, A. Renaut, A.W. Goode, and M. Sheaff The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators Surgery 134 2003 827 834
9. A.J. Marrogi, A. Munshi, A.J. Merogi, Y. Ohadoke, A. El Habashi, and O. Marrogi Study of tumour infiltrating lymphocytes and transforming growth factor-β as prognostic factor in breast cancer Int J Cancer 74 1997 492 501
10. S. Marsigliante, L. Biscozzo, A. Marra, G. Nicolardi, G. Leo, and G.B. Lobreglio Computerized counting of tumor infiltrating lymphocytes in 90 breast cancer specimens Cancer Lett 139 1999 33 41
11. J.B. Reome, J.C. Hylind, R.W. Dutton, and M.J. Dobrzanski Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer Clin Immunol 111 2004 69 81
12. P.Y. Wong, E.D. Staren, N. Tereshkova, and D. Braun Functional analysis of tumour-infiltrating leukocytes in breast cancer patients J Surg Res 1998 7695 7703
13. + T cells: potential effects on cancer immune surveillance and immunotherapy Cancer Immunol Immunother 53 2004 925 933
14. + Tregs and immune control J Clin Invest 114 2004 1209 1217
15. + T cells Hum Immunol 63 2002 1000 1009
16. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production J Exp Med 188 1998 287 296
17. U.K. Liyanage, T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, and G. Doherty Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 2002 2756 2761
18. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res 61 2001 4766 4772
19. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, and P. Mottram Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
20. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens J Immunother 26 2003 85 93
21. N.A. Marshall, L.E. Christie, L.R. Munro, D.J. Culligan, P.W. Johnston, and R.N. Barker Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma Blood 103 2004 1755 1762
22. + regulatory T cells are dependent on CTLA-4 expression Eur J Immunol 34 2004 3485 3496
23. + T cells with regulatory properties isolated from peripheral blood J Exp Med 193 2001 1285 1294
24. + regulatory T cells exert in vitro suppressive activity independent of CTLA-4 Int Immunol 17 2005 421 427
25. + regulatory T cells: thymus or periphery J Clin Invest 112 2003 1310 1312
26. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061
27. + T regulatory cells on development, functional activation, and proliferation of Th2 cells J Immunol 173 2004 267 274
28. + T regulatory cells in human Hum Immunol 66 2005 13 20
29. - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity Immunol Rev 182 2001 201 206
30. M. Hishii, J.T. Kurnick, T. Ramirez-Montagut, and F. Pandolfi Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes Clin Exp Immunol 116 1999 388 394
31. M. Terabe, and J.A. Berzofsky Immunoregulatory T cells in tumor immunity Curr Opin Immunol 16 2004 157 162
32. F. Ichihara, K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers Clin Cancer Res 9 2003 4404 4408
33. + Treg cells reveals an age-dependent loss of suppressive activity J Neurosci Res 74 2003 296 308
34. A. Matejuk, C. Hopke, A.A. Vandenbark, P.D. Hurn, and H. Offner Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy J Immunol 174 2005 2387 2395
35. L. Komlos, Z. Zahavi, D. Dicker, D. Luria, H. Salman, and I. Zahavi In vitro modulation of activation antigens on human lymphocytes by beta-estradiol Am J Reprod Immunol 40 1998 418 423
36. M.C. Erlandsson, C. Ohlsson, J.A. Gustafsson, and H. Carlsten Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus Immunology 103 2001 17 25
37. + regulatory T cell compartment J Immunol 173 2004 2227 2230
38. M.R. Walker, D.J. Kasprowicz, V.H. Gersuk, A. Benard, M. Van Landeghen, and J.H. Buckner Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells J Clin Invest 112 2003 1437 1443
39. G. Filaci, M. Fravega, S. Negrini, F. Procopio, D. Fenoglio, and M. Rizzi Indiveri F Nonantigeni specific CD8+ T suppressor lymphocytes originate from CD8+CD28-T cells and inhibit both T-cell proliferation and CTL function Hum Immunol 65 2004 142 156
40. - progeny, but IL-4 prevents loss of CD28 expression Int Immunol 11 1999 1327 1335
41. - lymphocytes in human immunodeficiency virus-specific cytotoxic activity J Virol 70 1996 2022 2026